← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Budesonide

Updated October 26, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Glucocorticoid with distinct inhaled airway and oral intestinal uses; veterinary studies address different species and formulations.

GlucocorticoidProduct-specific clinical reference

Formulation determines delivery to airways or intestine.

Key prescribing checks

  • Inhaled feline and equine studies reported adrenal-axis suppression.
  • The canine IBD trial did not demonstrate fewer owner-reported adverse effects than prednisone.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs

Extra-label veterinary evidence; not an animal product approval

Inflammatory bowel disease, oral

Randomized canine study evaluated a powder-based oral preparation.

Use / indication source ↗

Cats

Extra-label veterinary evidence; not an animal product approval

Asthma/chronic bronchitis, inhaled

Clinical observational study reported improvement and adrenal suppression in some cats.

Use / indication source ↗

Horses

Extra-label veterinary evidence; not an animal product approval

Severe asthma, inhaled

Experimental trials used a dedicated investigational device; do not assume device equivalence.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Glucocorticoid anti-inflammatory action.

Absorption, distribution, metabolism and elimination

CYP3A4 metabolism creates interaction potential. Oral formulation and hepatic function influence exposure; animal inhalation studies show systemic endocrine effects.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Budesonide Inhalation Suspension

Human inhaled label; animal use is extra-label.

Contraindications · when not to use

  • Ingredient hypersensitivity; not primary emergency asthma treatment.

Precautions & monitoring

  • Infection, adrenal suppression and paradoxical bronchospasm require assessment.

Budesonide Delayed-Release Capsules / Entocort EC

Human oral delayed-release label; not a veterinary regimen.

Contraindications · when not to use

  • Budesonide/component hypersensitivity.

Precautions & monitoring

  • Systemic steroid effects and increased exposure with liver impairment remain possible.

Inhaled delivery does not eliminate systemic steroid effects.

Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Adrenal suppression can occur even with inhaled treatment.

Canine IBD trial did not show an adverse-effect advantage over prednisone.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.

No animal dosing is supplied. The veterinarian must select the exact formulation, delivery device and individual regimen.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Compare with other medications and check species →

Budesonide Inhalation Suspension

Human inhaled label; animal use is extra-label.

  • Strong CYP3A4 inhibitors can increase corticosteroid exposure.
Interaction source ↗

Budesonide Delayed-Release Capsules / Entocort EC

Human oral delayed-release label; not a veterinary regimen.

  • Label advises avoiding CYP3A4 inhibitors, including itraconazole, erythromycin and cyclosporine.
Interaction source ↗

Monitoring

Track respiratory or intestinal response according to indication.

Veterinarian assessment for infection and systemic steroid effects.

Client counseling

This is not an acute bronchodilator.

Do not change route, compound, device or chronic steroid therapy without the veterinarian.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Follow the exact capsule or inhalation-container storage and handling instructions.

Brands, formulations & ingredient identity

Active ingredients

Budesonide

Other searchable names: Pulmicort · Pulmicort Respules · Entocort EC

Oral delayed-release capsules, compounded oral products and inhalation suspensions are not interchangeable.

The canine IBD trial used pure powder-based oral budesonide, not proof of equivalence to an enteric human capsule.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Budesonide Inhalation Suspension

Formulation
Nebulizer inhalation suspension
Label / product scope
Human product

Human product; veterinary use requires a prescription. Respules-style formulation; verify product.

Product label / source ↗

Budesonide Delayed-Release Capsules

Formulation
Oral delayed-release capsule
Label / product scope
Human product

Human product; veterinary use requires a prescription. Entocort EC-type presentation.

Product label / source ↗

References & review status

Clinical reference updated October 26, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

Search another medication or supplement →

CONTINUE EXPLORING

Use these connected guides to prepare informed questions for your veterinary team.

Find Veterinary Care Near YouLocate general practices, urgent-care clinics, emergency hospitals and specialists.Read resource →When It Is an EmergencyRecognize signs that require immediate veterinary care.Read resource →Interactive Symptom NavigatorStart with what you notice and understand when to seek help.Read resource →Poisons and Household HazardsRecognize common exposures and avoid unsafe home treatment.Read resource →Printable Owner ToolkitBring observations, medication details and questions to your appointment.Read resource →
Privacy & cookie choices